<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
        {font-family:"Cambria Math";
        panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
        {font-family:Calibri;
        panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
        {font-family:"Segoe UI";
        panose-1:2 11 5 2 4 2 4 2 2 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
        {margin:0in;
        margin-bottom:.0001pt;
        font-size:11.0pt;
        font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
        {mso-style-priority:99;
        color:#0563C1;
        text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
        {mso-style-priority:99;
        color:#954F72;
        text-decoration:underline;}
span.EmailStyle17
        {mso-style-type:personal-compose;
        font-family:"Calibri",sans-serif;
        color:windowtext;}
p.xmsonormal, li.xmsonormal, div.xmsonormal
        {mso-style-name:x_msonormal;
        margin:0in;
        margin-bottom:.0001pt;
        font-size:11.0pt;
        font-family:"Calibri",sans-serif;}
p.xxxmsonormal, li.xxxmsonormal, div.xxxmsonormal
        {mso-style-name:x_xxmsonormal;
        margin:0in;
        margin-bottom:.0001pt;
        font-size:11.0pt;
        font-family:"Calibri",sans-serif;}
p.xxxxxmsonormal, li.xxxxxmsonormal, div.xxxxxmsonormal
        {mso-style-name:x_xxxxmsonormal;
        margin:0in;
        margin-bottom:.0001pt;
        font-size:11.0pt;
        font-family:"Calibri",sans-serif;}
.MsoChpDefault
        {mso-style-type:export-only;
        font-family:"Calibri",sans-serif;}
@page WordSection1
        {size:8.5in 11.0in;
        margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
        {page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><img width="960" height="343" style="width:10.0in;height:3.5729in" id="x_x_x_Picture_x0020_1" src="cid:image001.jpg@01DCD7B0.20434E10" alt="cid:image001.jpg@01DC8A13.F18D6720"><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:10.0pt;font-family:"Segoe UI",sans-serif">Medicine and laboratory testing are constantly changing.  The Laboratory Formulary Committee regularly sends out emails with new updates and changes.  </span><o:p></o:p></p>
<p class="xxxmsonormal"><b><span style="color:black"> </span></b><o:p></o:p></p>
<p class="xxxxxmsonormal"><b><span style="color:black">ANA Specificity Testing Change</span></b><span style="color:black">: Starting
<b>April 30<sup>th</sup>, 2026</b>, the Immunology Laboratory at Upstate will be updating the
<b>ANA Specificity (LAB2800)</b> assay to include additional antibody specificities.  Additionally, the reporting format will be updated to include interpretation aids in the comments of each analyte testing result.  Please see the attached guidance for more
 details.</span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:10.0pt;font-family:"Segoe UI",sans-serif"> </span><o:p></o:p></p>
<p class="xxxxxmsonormal"><b><span style="font-size:10.0pt;font-family:"Segoe UI",sans-serif">TEG Viewer access update:</span></b><span style="font-size:10.0pt;font-family:"Segoe UI",sans-serif">  Following an updated security review, all appropriate providers
<u>should now have access to the TEG Viewer software to review TEG testing</u> in real time (<b>TEG Bleeding Risk (LAB12367)
</b>and<b> TEG Anti-Platelet Tx (LAB9687)</b>).<b>  </b>Previously, not all providers were able to access this application.  The attached guidance gives more details and step-by-step instructions to access this application.
</span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:10.0pt;font-family:"Segoe UI",sans-serif"> </span><o:p></o:p></p>
<p class="xxxxxmsonormal"><span style="font-size:10.0pt;font-family:"Segoe UI",sans-serif">For prior guidances, please visit
</span><a href="https://urldefense.com/v3/__https:/upstate0.sharepoint.com/sites/LaboratoryFormularyCommitteeLabchanges__;!!GobTDDpD7A!fMqwKEI3JlieL_eF-Vo4vMVj2PNzfXcL0GsxYMLCbL6cXpbRqzmyQKWIxbV1BBgJ8OlmOsFv$"><span style="font-size:10.0pt;font-family:"Segoe UI",sans-serif">https://upstate0.sharepoint.com/sites/LaboratoryFormularyCommitteeLabchanges</span></a><o:p></o:p></p>
</div>
</body>
</html>